Dyne Therapeutics, Inc. financial data

Symbol
DYN on Nasdaq
Industry
Pharmaceutical Preparations
Location
1560 Trapelo Road, Waltham, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
Q1 2024 - May 2, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 810 % -25.4%
Debt-to-equity 23.2 % +17.7%
Return On Equity -111 % -61.8%
Return On Assets -90 % -57.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 87.4 M shares +49.9%
Common Stock, Shares, Outstanding 87.1 M shares +49.4%
Entity Public Float 504 M USD +133%
Common Stock, Value, Issued 9 K USD +50%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 218 M USD +43.2%
General and Administrative Expense 48.1 M USD +68.2%
Operating Income (Loss) -266 M USD -47.2%
Net Income (Loss) Attributable to Parent -257 M USD -45.7%
Earnings Per Share, Basic -3.98 USD/shares -19.9%
Earnings Per Share, Diluted -3.98 USD/shares -19.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 272 M USD +50.2%
Assets, Current 488 M USD +95.9%
Property, Plant and Equipment, Net 4.58 M USD -17.8%
Operating Lease, Right-of-Use Asset 27.6 M USD -12.4%
Assets 522 M USD +80.9%
Accounts Payable, Current 7.21 M USD -17.7%
Employee-related Liabilities, Current 4.72 M USD +172%
Liabilities, Current 22.4 M USD +3.6%
Operating Lease, Liability, Noncurrent 21.9 M USD -13%
Liabilities 44.2 M USD -5.32%
Accumulated Other Comprehensive Income (Loss), Net of Tax -132 K USD +35%
Retained Earnings (Accumulated Deficit) -698 M USD -58.4%
Stockholders' Equity Attributable to Parent 478 M USD +97.6%
Liabilities and Equity 522 M USD +80.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -78.5 M USD -67.4%
Net Cash Provided by (Used in) Financing Activities 408 M USD +1317%
Net Cash Provided by (Used in) Investing Activities -180 M USD -765%
Common Stock, Shares Authorized 200 M shares 0%
Common Stock, Shares, Issued 87.1 M shares +49.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 150 M USD +1573%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 274 M USD +49.3%
Deferred Tax Assets, Valuation Allowance 146 M USD +28.3%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 152 M USD +24%
Operating Lease, Liability 27.4 M USD -10.1%
Payments to Acquire Property, Plant, and Equipment 191 K USD -17%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -257 M USD -46.2%
Lessee, Operating Lease, Liability, to be Paid 32.8 M USD -12.6%
Property, Plant and Equipment, Gross 10.3 M USD +6.82%
Operating Lease, Liability, Current 4.76 M USD +2.41%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.99 M USD +3.01%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.85 M USD +2.41%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 5.36 M USD -23.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.14 M USD +3%
Deferred Tax Assets, Operating Loss Carryforwards 57.5 M USD -4.21%
Preferred Stock, Shares Authorized 10 M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.3 M USD +2.99%
Operating Lease, Payments 4.63 M USD +42.7%
Additional Paid in Capital 1.18 B USD +72.3%
Depreciation, Depletion and Amortization 1.65 M USD -1.38%
Deferred Tax Assets, Net of Valuation Allowance 6.01 M USD -31.7%
Share-based Payment Arrangement, Expense 35.3 M USD +130%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%